BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13512. [PMID: 30817026 DOI: 10.1111/ctr.13512] [Cited by in Crossref: 124] [Cited by in F6Publishing: 104] [Article Influence: 41.3] [Reference Citation Analysis]
Number Citing Articles
1 Lv T, Xu X, Song J, Tan Y, Jiang L, Yang J, He D, Kong L, Zhang W, Chen P, Xiang Q, Zhu T, Wu H, Wen T, Yang J. Use of donor-specific red blood cell transfusions for patients undergoing liver transplantation during the COVID-19 pandemic. Hepatobiliary Surg Nutr 2021;10:486-97. [PMID: 34430527 DOI: 10.21037/hbsn-21-190] [Reference Citation Analysis]
2 Fida N, Tantrachoti P, Guha A, Bhimaraj A. Post-transplant Management in Heart Transplant Recipients: New Drugs and Prophylactic Strategies. Curr Treat Options Cardio Med 2021;23. [DOI: 10.1007/s11936-021-00933-2] [Reference Citation Analysis]
3 Lizaola-Mayo BC, Rodriguez EA. Cytomegalovirus infection after liver transplantation. World J Transplant 2020; 10(7): 183-190 [PMID: 32844094 DOI: 10.5500/wjt.v10.i7.183] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Schaenman J, Phonphok K, Spanuchart I, Duong T, Sievers TM, Lum E, Reed EF, Bunnapradist S. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients. Transpl Infect Dis 2021;23:e13457. [PMID: 32892447 DOI: 10.1111/tid.13457] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Ajlan A, Aleid H, Ali TZ, Joharji H, Almeshari K, Nazmi AM, Shah Y, Devol E, Alkortas D, Alabdulkarim Z, Broering D, Alahmadi I, Ullah A, Alotaibi A, Aljedai A. Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial. Trials 2021;22:414. [PMID: 34167567 DOI: 10.1186/s13063-021-05253-1] [Reference Citation Analysis]
6 Manuel O, Avery RK. Update on cytomegalovirus in transplant recipients: new agents, prophylaxis, and cell-mediated immunity. Curr Opin Infect Dis 2021;34:307-13. [PMID: 34074879 DOI: 10.1097/QCO.0000000000000746] [Reference Citation Analysis]
7 Wang R, Longworth SA, Doyon JB, Lee I, Bloom RD, Romano CM, Veasey SL, Blumberg EA. Active Tuberculosis After Solid Organ Transplantation in Individuals With Negative Pretransplant QuantiFERON-TB Gold Testing: A Case Series. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2021.11.030] [Reference Citation Analysis]
8 Singh P, Bentall AJ, Langstraat CL, Swanson AA, Deziel PJ, Huang Y, Razonable RR. A rare manifestation of CMV disease in a kidney transplant recipient. Transpl Infect Dis 2021;23:e13527. [PMID: 33237608 DOI: 10.1111/tid.13527] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Carbo EC, Russcher A, Kraakman MEM, de Brouwer CS, Sidorov IA, Feltkamp MCW, Kroes ACM, Claas ECJ, de Vries JJC. Longitudinal Monitoring of DNA Viral Loads in Transplant Patients Using Quantitative Metagenomic Next-Generation Sequencing. Pathogens 2022;11:236. [DOI: 10.3390/pathogens11020236] [Reference Citation Analysis]
10 Altunisik Toplu S, Kose A, Karakas S, Bayindir Y, Otlu B, Yilmaz S. Evaluation of Cytomegalovirus Infections in Liver Transplant Recipients Under Universal Prophylaxis: A Single Centre Experience. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.115370] [Reference Citation Analysis]
11 Christensen BW, Li HC, Huerta S. Blurred Vision and Gastrointestinal Bleeding in a Patient With HIV. JAMA 2022;327:276-7. [PMID: 35040904 DOI: 10.1001/jama.2021.21510] [Reference Citation Analysis]
12 Hemmersbach-Miller M, Alexander BD, Pieper CF, Schmader KE. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient. Eur J Clin Microbiol Infect Dis 2020;39:455-63. [PMID: 31758441 DOI: 10.1007/s10096-019-03744-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Kaviani A, Ince D, Axelrod DA. Management of Antimicrobial Agents in Abdominal Organ Transplant Patients in Intensive Care Unit. Curr Transplant Rep 2020;7:1-11. [PMID: 32432022 DOI: 10.1007/s40472-020-00268-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Munting A, Manuel O. Viral infections in lung transplantation. J Thorac Dis 2021;13:6673-94. [PMID: 34992844 DOI: 10.21037/jtd-2021-24] [Reference Citation Analysis]
15 Liverman R, Chandran MM, Crowther B. Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient. Pharmacotherapy 2021;41:77-102. [PMID: 33151553 DOI: 10.1002/phar.2483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bruminhent J, Worawichawong S, Tongsook C, Pasomsub E, Boongird S, Watcharananan SP. Epidemiology and Outcomes of Early-Onset and Late-Onset Adenovirus Infections in Kidney Transplant Recipients. Open Forum Infect Dis 2019;6:ofz489. [PMID: 32128332 DOI: 10.1093/ofid/ofz489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
17 Fallahzadeh MA, Rico NT, Vahhab E, He H, Elhamahmi DA, Sandkovsky U. Strongyloides stercoralis and cytomegalovirus coinfection in a patient with a transplanted kidney. Baylor University Medical Center Proceedings 2022;35:190-2. [DOI: 10.1080/08998280.2021.1997262] [Reference Citation Analysis]
18 Stern A, Papanicolaou GA. CMV Prevention and Treatment in Transplantation: What's New in 2019. Curr Infect Dis Rep 2019;21:45. [PMID: 31732823 DOI: 10.1007/s11908-019-0699-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
19 Singha A, Burcham PK, Logan A, El Boghdadly Z, Howsare MM, Nunley DR, Lustberg ME, Keller BC. Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia. Transplantology 2021;2:129-39. [DOI: 10.3390/transplantology2020013] [Reference Citation Analysis]
20 Fisher MA, Lloyd ML. A Review of Murine Cytomegalovirus as a Model for Human Cytomegalovirus Disease-Do Mice Lie? Int J Mol Sci 2020;22:E214. [PMID: 33379272 DOI: 10.3390/ijms22010214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 AbdulRahim N, McAdams M, Xu P, Wojciechowski D, La Hoz RM, Lu C, Vazquez MA, Hedayati SS. Association of Inflammatory Biomarkers with Immunosuppression Management and Outcomes in Kidney Transplant Recipients with COVID-19. Transplant Proc 2021;53:2451-67. [PMID: 34465422 DOI: 10.1016/j.transproceed.2021.08.002] [Reference Citation Analysis]
22 Mullane KM. Human Cytomegalovirus Prophylaxis and Treatment in Lung Transplantation in the Current Era. Curr Pulmonol Rep 2020;9:10-27. [DOI: 10.1007/s13665-020-00246-y] [Reference Citation Analysis]
23 Charlotte R, François P, Jonathan M, Véronique B, Olivier B, Tristan D, Séverine F, Jérôme L, Adrien T, Claire D, Espérie B, Eve C, Antoine R. Use of anti-CMV immunoglobulins in lung transplant recipients: The French experience. Transpl Infect Dis 2021;:e13754. [PMID: 34723405 DOI: 10.1111/tid.13754] [Reference Citation Analysis]
24 Fernández-Ruiz M, Rodríguez-Goncer I, Parra P, Ruiz-Merlo T, Corbella L, López-Medrano F, Polanco N, González E, San Juan R, Folgueira MD, Andrés A, Aguado JM. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin. Am J Transplant 2020;20:2070-80. [PMID: 31991045 DOI: 10.1111/ajt.15793] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
25 Santhanakrishnan K, Yonan N, Iyer K, Callan P, Al-Aloul M, Venkateswaran R. Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review. Transpl Infect Dis 2021;:e13733. [PMID: 34534396 DOI: 10.1111/tid.13733] [Reference Citation Analysis]
26 Stamps H, Linder K, O'Sullivan DM, Serrano OK, Rochon C, Ebcioglu Z, Singh J, Ye X, Tremaglio J, Sheiner P, Cheema F, Kutzler HL. Evaluation of cytomegalovirus prophylaxis in low and intermediate risk kidney transplant recipients receiving lymphocyte-depleting induction. Transpl Infect Dis 2021;:e13573. [PMID: 33527728 DOI: 10.1111/tid.13573] [Reference Citation Analysis]
27 Valencia Deray KG, Hosek KE, Chilukuri D, Dunson JR, Spielberg DR, Swartz SJ, Spinner JA, Leung DH, Moulton EA, Munoz FM, Demmler-Harrison GJ, Bocchini CE. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant 2021. [PMID: 34467658 DOI: 10.1111/ajt.16822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Houldcroft CJ, Jackson SE, Lim EY, Sedikides GX, Davies EL, Atkinson C, McIntosh M, Remmerswaal EBM, Okecha G, Bemelman FJ, Stanton RJ, Reeves M, Wills MR. Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay. Front Cell Infect Microbiol 2020;10:275. [PMID: 32670891 DOI: 10.3389/fcimb.2020.00275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wetwittayakhlang P, Rujeerapaiboon N, Wetwittayakhlung P, Sripongpun P, Pruphetkaew N, Jandee S, Chamroonkul N, Piratvisuth T. Clinical Features, Endoscopic Findings, and Predictive Factors for Mortality in Tissue-Invasive Gastrointestinal Cytomegalovirus Disease between Immunocompetent and Immunocompromised Patients. Gastroenterol Res Pract 2021;2021:8886525. [PMID: 33897776 DOI: 10.1155/2021/8886525] [Reference Citation Analysis]
30 Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Limaye AP. Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. J Infect Dis 2021;223:1073-7. [PMID: 32726431 DOI: 10.1093/infdis/jiaa470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Karaba AH, Figueroa A, Werbel WA, Dioverti MV, Steinke SM, Ray SC, Cox AL, Avery RK. Interleukin-18 and tumor necrosis factor-α are elevated in solid organ transplant recipients with possible cytomegalovirus end-organ disease. Transpl Infect Dis 2021;:e13682. [PMID: 34216086 DOI: 10.1111/tid.13682] [Reference Citation Analysis]
32 Otokubo M, Wada K, Ikura M, Hayase K, Uno T, Nakagita K, Hayakawa N, Watanabe T, Seguchi O, Fukushima N, Nakamura T. Risk Assessment of Neutropenia during Low-Dose Valganciclovir Prophylaxis for Heart Transplant Recipients. Biological & Pharmaceutical Bulletin 2022;45:452-9. [DOI: 10.1248/bpb.b21-00860] [Reference Citation Analysis]
33 Mourik K, Boers S, van Rijn A, Thijssen J, Doorn R, Svraka S, Bart A, Wessels E, Claas E, Nijhuis R. Evaluation of the sample-to-result, random access NeuMoDx platform for viral load testing of Cytomegalovirus and Epstein Barr virus in clinical specimens. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105122] [Reference Citation Analysis]
34 Taksinwarajarn T, Sobhonslidsuk A, Kantachuvesiri S, Thongprayoon C, Cheungpasitporn W, Bruminhent J; Ramathibodi Transplant Infectious Diseases (RTID) group. Role of highly sensitive nucleic acid amplification testing for plasma cytomegalovirus DNA load in diagnosis of cytomegalovirus gastrointestinal disease among kidney transplant recipients. Transpl Infect Dis 2021;:e13635. [PMID: 33982825 DOI: 10.1111/tid.13635] [Reference Citation Analysis]
35 Azhar A, Tsujita M, Talwar M, Balaraman V, Bhalla A, Eason JD, Nouer SS, Sumida K, Remport A, Hall IE, Griffin R, Rofaiel G, Molnar MZ. CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors. Ren Fail 2022;44:831-41. [PMID: 35546431 DOI: 10.1080/0886022X.2022.2072744] [Reference Citation Analysis]
36 Ryu H, Narayanan N, Bhatt PJ. Prevention of infection and optimizing vaccination in the solid organ transplant candidate and recipient. Curr Opin Organ Transplant 2021;26:445-55. [PMID: 34227584 DOI: 10.1097/MOT.0000000000000902] [Reference Citation Analysis]
37 Oltean M, Søfteland JM, Bagge J, Ekelund J, Felldin M, Schult A, Magnusson J, Friman V, Karason K. Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic. Infect Dis (Lond) 2020;52:830-7. [PMID: 32657186 DOI: 10.1080/23744235.2020.1792977] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
38 Shah S, DeBerge M, Iovane A, Yan S, Qiu L, Wang JJ, Kanwar YS, Hummel M, Zhang ZJ, Abecassis MM, Luo X, Thorp EB. MCMV Dissemination from Latently-Infected Allografts Following Transplantation into Pre-Tolerized Recipients. Pathogens 2020;9:E607. [PMID: 32722544 DOI: 10.3390/pathogens9080607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Varnas D, Jankauskienė A. Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review. Acta Med Litu 2021;28:136-44. [PMID: 34393636 DOI: 10.15388/Amed.2020.28.1.5] [Reference Citation Analysis]
40 Waters S, Lee S, Lloyd M, Irish A, Price P. The Detection of CMV in Saliva Can Mark a Systemic Infection with CMV in Renal Transplant Recipients. Int J Mol Sci 2019;20:E5230. [PMID: 31652514 DOI: 10.3390/ijms20205230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Osterholm EA, Schleiss MR. Impact of breast milk-acquired cytomegalovirus infection in premature infants: Pathogenesis, prevention, and clinical consequences? Rev Med Virol 2020;30:1-11. [PMID: 32662174 DOI: 10.1002/rmv.2117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Vutien P, Perkins J, Biggins SW, Reyes J, Imlay H, Limaye AP. Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. Liver Transpl 2021;27:1302-11. [PMID: 33687777 DOI: 10.1002/lt.26045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Razonable RR, Inoue N, Pinninti SG, Boppana SB, Lazzarotto T, Gabrielli L, Simonazzi G, Pellett PE, Schmid DS. Clinical Diagnostic Testing for Human Cytomegalovirus Infections. J Infect Dis 2020;221:S74-85. [PMID: 32134488 DOI: 10.1093/infdis/jiz601] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
44 Shaikh AS, Shaim H, Caravedo MA, Ong KM, Reynoso D. A New Viral Coinfection: SARS-CoV-2 Pneumonia and Cytomegalovirus Pneumonitis in a Renal Transplant Recipient. COVID 2021;1:115-9. [DOI: 10.3390/covid1010010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
45 Boutolleau D, Coutance G, Désiré E, Bouglé A, Bréchot N, Leprince P, Varnous S. Association between cytomegalovirus infection and allograft rejection in a large contemporary cohort of heart transplant recipients. Transpl Infect Dis 2021;:e13569. [PMID: 33452851 DOI: 10.1111/tid.13569] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Abbas A, Zimmer AJ, Florescu D. Viral Enteritis in Solid-Organ Transplantation. Viruses 2021;13:2019. [PMID: 34696449 DOI: 10.3390/v13102019] [Reference Citation Analysis]
47 Silva F, Ficher KN, Viana L, Coelho I, Rezende JT, Wagner D, Vaz ML, Foresto R, Silva Junior HT, Pestana JM. Presumed cytomegalovirus retinitis late after kidney transplant. J Bras Nefrol 2021:S0101-28002021005039302. [PMID: 33973995 DOI: 10.1590/2175-8239-JBN-2020-0254] [Reference Citation Analysis]
48 Alfieri CM, Molinari P, Gandolfo M, Campise M, Cresseri D, Regalia A, Favi E, Li M, Ikehata M, Delbue S, Messa P. Cytomegalovirus Disease in Renal Transplanted Patients: Prevalence, Determining Factors, and Influence on Graft and Patients Outcomes. Pathogens 2021;10:473. [PMID: 33919676 DOI: 10.3390/pathogens10040473] [Reference Citation Analysis]
49 Di Cristanziano V, Affeldt P, Trappe M, Wirtz M, Heger E, Knops E, Kaiser R, Stippel D, Müller RU, Holtick U, Scheid C, Kann M, Kurschat CE, Grundmann F. Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients. Microorganisms 2021;9:1666. [PMID: 34442744 DOI: 10.3390/microorganisms9081666] [Reference Citation Analysis]
50 Rahimishahmirzadi M, Jevnikar AM, House AA, Luke PP, Humar A, Silverman MS, Shalhoub SM, Hosseini-Moghaddam SM. Late-onset allograft rejection, cytomegalovirus infection, and renal allograft loss: Is anti-CMV prophylaxis required following late-onset allograft rejection? Clin Transplant 2021;35:e14285. [PMID: 33713374 DOI: 10.1111/ctr.14285] [Reference Citation Analysis]
51 Han MS, Choi EH, Lee HJ, Yun KW, Kang HJ, Hong KT, Choi JY, Shin HY. Cytomegalovirus disease in a retinoblastoma cohort: The role of preemptive screening. Pediatr Blood Cancer 2020;67:e28101. [PMID: 31793213 DOI: 10.1002/pbc.28101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Hakki M, Aitken SL, Danziger-Isakov L, Michaels MG, Carpenter PA, Chemaly RF, Papanicolaou GA, Boeckh M, Marty FM. American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. Transplant Cell Ther 2021;27:707-19. [PMID: 34452721 DOI: 10.1016/j.jtct.2021.05.001] [Reference Citation Analysis]
53 Jorgenson MR, Marka N, Leverson GE, Smith JA, Odorico JS. Valganciclovir prophylaxis extension from 3 to 6 months in high-risk pancreas-transplant recipients does not impact incidence of cytomegalovirus infection at 12 months. Clin Transplant 2021;:e14379. [PMID: 34075624 DOI: 10.1111/ctr.14379] [Reference Citation Analysis]
54 Rezzouk B, Bouattar T, Belkadi B, Razine R, Bayahia R, Ouzeddoun N, Benamar L, Rhou H, Bouihat N, Ibrahimi A, Seffar M, Kabbaj H. Characteristics and Outcomes of Cytomegalovirus Infection in Seropositive Kidney Transplant Recipients in the Era of Antiviral Prophylaxis with Valacyclovir: A Single-Center Study in Morocco. TRRM 2021;Volume 13:1-13. [DOI: 10.2147/trrm.s278655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
55 Lier AJ, Virmani S, Ilagan-Ying Y, Leelatian N, Darbinyan A, Malinis MF. Unilateral leg pain caused by cryptococcal myositis: An unusual presentation of disseminated cryptococcosis in a kidney transplant recipient. Transpl Infect Dis 2021;23:e13491. [PMID: 33040432 DOI: 10.1111/tid.13491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Albekairy AM, Shawaqfeh MS, Alharbi SH, Almuqbil F, Alghamdi MA, Albekairy NA, Muflih SM, Alkatheri A. Prophylaxis of Cytomegalovirus Infection in Solid Organ Transplantation, Retrospective Evaluation. TRRM 2022;Volume 14:35-45. [DOI: 10.2147/trrm.s366213] [Reference Citation Analysis]
57 Durst MM, Jorgenson MR, Descourouez JL, Saddler CM, Smith JA, Odorico JS, Mandelbrot DA. Bimonthly viral monitoring for late-onset cytomegalovirus infection-Balancing efficacy with patient palatability; A reply to Melgarejo et al. Clin Transplant 2021;:e14348. [PMID: 34019715 DOI: 10.1111/ctr.14348] [Reference Citation Analysis]
58 Jorgenson MR, Wong C, Descourouez JL, Saddler CM, Smith JA, Mandelbrot DA. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation. Transpl Infect Dis 2021;:e13617. [PMID: 33866643 DOI: 10.1111/tid.13617] [Reference Citation Analysis]
59 Bixby AL, Fitzgerald L, Park JM, Kaul D, Tischer S. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2021;23:e13713. [PMID: 34428337 DOI: 10.1111/tid.13713] [Reference Citation Analysis]
60 Jorgenson MR, Parajuli S, Marka N, Leverson GE, Smith JA, Mandelbrot DA, Odorico JS. Geographic Distribution of Cytomegalovirus Serology in Kidney and Pancreas Transplant Recipients in the United States. Transplant Direct 2021;7:e704. [PMID: 34056079 DOI: 10.1097/TXD.0000000000001147] [Reference Citation Analysis]
61 Kirisri S, Vongsakulyanon A, Kantachuvesiri S, Razonable RR, Bruminhent J. Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity. Open Forum Infect Dis 2021;8:ofab199. [PMID: 34113686 DOI: 10.1093/ofid/ofab199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Melgarejo I, Jorgensen D, Hariharan S, Puttarajappa CM. Bimonthly viral monitoring for late-onset cytomegalovirus infection in kidney transplant recipients. Clin Transplant 2021;35:e14259. [PMID: 33605490 DOI: 10.1111/ctr.14259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Lease ED, Budev MM. Infectious Complications in Lung Transplant Recipients. Thorac Surg Clin 2022;32:211-20. [PMID: 35512939 DOI: 10.1016/j.thorsurg.2021.12.002] [Reference Citation Analysis]
64 Saeed MI, Stephens R, Nwogbo O, Gani IY, Kapoor R, Doroodchi A. Cytomegalovirus pancreatitis in an immunocompetent patient. IDCases 2020;22:e00932. [PMID: 33299793 DOI: 10.1016/j.idcr.2020.e00932] [Reference Citation Analysis]
65 Santhanakrishnan K, Yonan N, Callan P, Karimi E, Al-aloul M, Venkateswaran R. The use of CMVIg rescue therapy in cardiothoracic transplantation: A single‐center experience over 6 years (2011‐2017). Clin Transplant 2019;33. [DOI: 10.1111/ctr.13655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Loy V. Spotlight on Impactful Research: Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Liver Transplantation Recipients. Clin Liver Dis (Hoboken) 2021;17:53-6. [PMID: 33680435 DOI: 10.1002/cld.962] [Reference Citation Analysis]
67 Nuansri S, Kantachuvesiri S, Watcharananan SP, Thongprayoon C, Cheungpasitporn W, Bruminhent J. Clinical Characteristics of Late-Onset Cytomegalovirus Infection After Kidney Transplantation. Transplant Proc 2021;53:2267-71. [PMID: 34404538 DOI: 10.1016/j.transproceed.2021.07.033] [Reference Citation Analysis]
68 Ruenroengbun N, Sapankaew T, Chaiyakittisopon K, Phoompoung P, Ngamprasertchai T. Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Front Cell Infect Microbiol 2022;12:865735. [DOI: 10.3389/fcimb.2022.865735] [Reference Citation Analysis]
69 Jorgenson MR, Descourouez JL, Brady BL, Chandran MM, Do V, Kim M, Laub MR, Lichvar A, Park JM, Szczepanik A, Alloway RR. A call for transplant stewardship: The need for expanded evidence-based evaluation of induction and biologic-based cost-saving strategies in kidney transplantation and beyond. Clin Transplant 2021;:e14372. [PMID: 34033140 DOI: 10.1111/ctr.14372] [Reference Citation Analysis]
70 Gleeson SE, Formica RN, Marin EP. Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic. Clin J Am Soc Nephrol 2020;15:892-5. [PMID: 32345749 DOI: 10.2215/CJN.04510420] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
71 Suàrez-Fernández P, Utrero-Rico A, Sandonis V, García-Ríos E, Arroyo-Sánchez D, Fernández-Ruiz M, Andrés A, Polanco N, González-Cuadrado C, Almendro-Vázquez P, Pérez-Romero P, Aguado JM, Paz-Artal E, Laguna-Goya R. Circulatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients. Am J Transplant 2021. [PMID: 34153157 DOI: 10.1111/ajt.16725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Haidar G, Boeckh M, Singh N. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence. J Infect Dis 2020;221:S23-31. [PMID: 32134486 DOI: 10.1093/infdis/jiz454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
73 Bruminhent J, Autto S, Rotjanapan P, Ngarmjanyaporn P, Bushyakanist A, Kirdlarp S, O-Charoen P, Setthaudom C, Pisitkun P. A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants. Open Forum Infect Dis 2021;8:ofab248. [PMID: 34189173 DOI: 10.1093/ofid/ofab248] [Reference Citation Analysis]
74 Dhital R, Anand S, Graber B, Zeng Q, Velazquez VM, Boddeda SR, Fitch JR, Minz RW, Minz M, Sharma A, Cianciolo R, Shimamura M. Murine cytomegalovirus promotes renal allograft inflammation via Th1/17 cells and IL-17A. Am J Transplant 2022. [PMID: 35671112 DOI: 10.1111/ajt.17116] [Reference Citation Analysis]
75 Rabbani N, Kronmal RA, Wagner T, Kemna M, Albers EL, Hong B, Friedland-Little J, Spencer K, Law YM. Association Between Cytomegalovirus Serostatus, Antiviral Therapy, and Allograft Survival in Pediatric Heart Transplantation. Transpl Int 2022;35:10121. [PMID: 35368645 DOI: 10.3389/ti.2022.10121] [Reference Citation Analysis]
76 Jorgenson MR, Kleiboeker H, Garg N, Parajuli S, Mandelbrot DA, Odorico JS, Saddler CM, Smith JA. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity. Transpl Infect Dis 2021;:e13766. [PMID: 34799964 DOI: 10.1111/tid.13766] [Reference Citation Analysis]
77 Räihä J, Ortiz F, Mannonen L, Loginov R, Lempinen M, Lautenschlager I, Helanterä I. The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis. Transpl Infect Dis 2021;:e13577. [PMID: 33527660 DOI: 10.1111/tid.13577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Filippidis P, Vionnet J, Manuel O, Mombelli M. Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34854329 DOI: 10.1080/14787210.2022.2013808] [Reference Citation Analysis]
79 Peddu V, Bradley BT, Casto AM, Shree R, Colbert BG, Xie H, Santo TK, Huang ML, Cheng EY, Konnick E, Salipante SJ, Jerome KR, Lockwood CM, Greninger AL. High-resolution profiling of human cytomegalovirus cell-free DNA in human plasma highlights its exceptionally fragmented nature. Sci Rep 2020;10:3734. [PMID: 32111931 DOI: 10.1038/s41598-020-60655-6] [Reference Citation Analysis]
80 Scarpini S, Morigi F, Betti L, Dondi A, Biagi C, Lanari M. Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice. Vaccines (Basel) 2021;9:551. [PMID: 34070277 DOI: 10.3390/vaccines9060551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Jorgenson MR, Hillis MI, Saddler CM, Smith JA, Parajuli S, Mandelbrot DA. Prediction of cytomegalovirus infection: A single‐center experience utilizing a newly available cell‐mediated immunity assay by flow cytometry, a risk factor screening tool, and serologically demonstrated immunity. Transpl Infect Dis 2020;22. [DOI: 10.1111/tid.13311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Ahn B, Yun KW, Hong KT, Choi JY, Kang HJ, Seong MW, Kim TS, Ahn SJ, Choi EH. Threshold of Quantitative Cytomegalovirus DNA PCR for Preemptive Treatment in Pediatric Hematopoietic Stem Cell Transplant Recipients. J Pediatr Hematol Oncol 2022. [PMID: 35482472 DOI: 10.1097/MPH.0000000000002467] [Reference Citation Analysis]
83 Fernández-Ruiz M, Aguado JM. Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis. Infect Dis Clin North Am 2020;34:191-210. [PMID: 32334982 DOI: 10.1016/j.idc.2020.02.002] [Reference Citation Analysis]
84 Jorgenson MR, Descourouez JL, Schulz LT, Goldrosen KA, Rice JP, Redfield RR, Saddler CM, Smith JA, Mandelbrot DA. The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients. Infect Control Hosp Epidemiol 2020;41:1068-74. [DOI: 10.1017/ice.2020.203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
85 Healy ZR, Weinhold KJ, Murdoch DM. Transcriptional Profiling of CD8+ CMV-Specific T Cell Functional Subsets Obtained Using a Modified Method for Isolating High-Quality RNA From Fixed and Permeabilized Cells. Front Immunol 2020;11:1859. [PMID: 32983102 DOI: 10.3389/fimmu.2020.01859] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Yamada M, Pellett Madan R. CMV as culprit or bystander: The debate continues. Pediatr Transplant 2020;24:e13865. [PMID: 33044777 DOI: 10.1111/petr.13865] [Reference Citation Analysis]
87 Altaf M, Lineburg KE, Crooks P, Rehan S, Matthews KK, Neller MA, Ambalathingal GR, Sinha D, Grant M, Hopkins PMA, Chambers D, Khanna R, Smith C. Pretransplant Cytomegalovirus-Specific Cellular Immunity and Risk of Viral Reactivation Following Lung Transplantation: A Prospective Cohort Study. The Journal of Infectious Diseases 2021;224:312-7. [DOI: 10.1093/infdis/jiaa750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
88 Trachuk P, Bartash R, Abbasi M, Keene A. Infectious Complications in Lung Transplant Recipients. Lung 2020;198:879-87. [PMID: 33169174 DOI: 10.1007/s00408-020-00403-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
89 Jorgenson MR, Descourouez JL, Garg N, Parajuli S, Mandelbrot DA, Odorico JS, Saddler CM, Smith JA. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. Transpl Infect Dis 2021;:e13693. [PMID: 34309158 DOI: 10.1111/tid.13693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Pearston AP, Ingemi AI, Ripley K, Wilson TJ, Gruber J, McMahon M, Sutton S, Khardori N. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report. Transplant Proc 2021;53:1284-7. [PMID: 33715819 DOI: 10.1016/j.transproceed.2021.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
91 Isberner N, Van Daele R, Klinker H, Kraus S, Aghai F, De Vlieger G, Kuypers D, Debaveye Y, Spriet I. Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy. J Antimicrob Chemother 2021;76:3322-5. [PMID: 34473284 DOI: 10.1093/jac/dkab316] [Reference Citation Analysis]
92 Cheng WY, Avery RK, Thompson-Leduc P, Cheung HC, Bo T, Duh MS, Hirji I. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation. J Med Econ 2022;:1-39. [PMID: 35240904 DOI: 10.1080/13696998.2022.2046388] [Reference Citation Analysis]
93 Gökler J, Aliabadi-Zuckermann A, Zuckermann A, Osorio E, Knobler R, Moayedifar R, Angleitner P, Leitner G, Laufer G, Worel N. Extracorporeal Photopheresis With Low-Dose Immunosuppression in High-Risk Heart Transplant Patients-A Pilot Study. Transpl Int 2022;35:10320. [PMID: 35401042 DOI: 10.3389/ti.2022.10320] [Reference Citation Analysis]
94 Otto WR, Green A. Antiviral Therapeutics in Pediatric Transplant Recipients. Infectious Disease Clinics of North America 2022;36:125-46. [DOI: 10.1016/j.idc.2021.11.004] [Reference Citation Analysis]
95 Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial. JAMA 2020;323:1378-87. [PMID: 32286644 DOI: 10.1001/jama.2020.3138] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 20.5] [Reference Citation Analysis]
96 Ahn R, Schaenman J, Qian Z, Pickering H, Groysberg V, Rossetti M, Llamas M, Hoffmann A, Gjertson D, Deng M, Bunnapradist S, Reed EF; CMV Systems Immunobiology Group. Acute and Chronic Changes in Gene Expression After CMV DNAemia in Kidney Transplant Recipients. Front Immunol 2021;12:750659. [PMID: 34867983 DOI: 10.3389/fimmu.2021.750659] [Reference Citation Analysis]
97 Boonsathorn S, Pasomsub E, Techasaensiri C, Apiwattanakul N. Analysis of Ganciclovir-Resistant Cytomegalovirus Infection Caused by the UL97 Gene Mutation in Codons 460 and 520 in Pediatric Patients: A Case Series. Open Forum Infect Dis 2019;6:ofz480. [PMID: 32528998 DOI: 10.1093/ofid/ofz480] [Reference Citation Analysis]
98 Rosenzweig M, Wall A, Spak CW, Testa G, Johannesson L. Pregnancy after CMV infection following uterus transplantation: A case report from the Dallas Uterus Transplant Study. Transpl Infect Dis 2021;23:e13653. [PMID: 34038016 DOI: 10.1111/tid.13653] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Carvalho-Gomes Â, Cubells A, Pallarés C, Corpas-Burgos F, Berenguer M, Aguilera V, López-Labrador FX. Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation. Cell Immunol 2021;371:104455. [PMID: 34864514 DOI: 10.1016/j.cellimm.2021.104455] [Reference Citation Analysis]
100 Chuleerarux N, Thongkam A, Manothummetha K, Nematollahi S, Dioverti-Prono V, Torvorapanit P, Langsiri N, Worasilchai N, Plongla R, Chindamporn A, Sanguankeo A, Permpalung N. Does Post-Transplant Cytomegalovirus Increase the Risk of Invasive Aspergillosis in Solid Organ Transplant Recipients? A Systematic Review and Meta-Analysis. J Fungi (Basel) 2021;7:327. [PMID: 33922773 DOI: 10.3390/jof7050327] [Reference Citation Analysis]
101 Chih S, McDonald M, Dipchand A, Kim D, Ducharme A, Kaan A, Abbey S, Toma M, Anderson K, Davey R, Mielniczuk L, Campbell P, Zieroth S, Bourgault C, Badiwala M, Clarke B, Belanger E, Carrier M, Conway J, Doucette K, Giannetti N, Isaac D, MacArthur R, Senechal M. Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care. Can J Cardiol 2020;36:335-56. [PMID: 32145863 DOI: 10.1016/j.cjca.2019.12.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
102 Onpoaree N, Sanpavat A, Sintusek P. Cytomegalovirus infection in liver-transplanted children. World J Hepatol 2022; 14(2): 338-353 [DOI: 10.4254/wjh.v14.i2.338] [Reference Citation Analysis]
103 Dorsey YC, Oloruntoba O, Pendse AA, King LY. More Than Meets the Eye? Clin Liver Dis (Hoboken) 2021;18:173-8. [PMID: 34745573 DOI: 10.1002/cld.1107] [Reference Citation Analysis]
104 Jo H, Kwon DE, Han SH, Min SY, Hong YM, Lim BJ, Lee KH, Jo JH. De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance. J Infect Dis 2020;221:1480-7. [PMID: 31802131 DOI: 10.1093/infdis/jiz642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
105 Jorgenson MR, Descourouez JL, Leverson GE, Saddler CM, Smith JA, Garg N, Parajuli S, Mandelbrot DA, Odorico JS. A pilot study of an intensified ganciclovir dosing strategy for treatment of cytomegalovirus disease in kidney and/or pancreas transplant recipients. Clin Transplant 2021. [PMID: 34263938 DOI: 10.1111/ctr.14427] [Reference Citation Analysis]
106 Jorgenson MR, Descourouez JL, Yang DY, Stalter LN, Leverson GE, Parajuli S, Mandelbrot DA, Smith JA, Redfield RR. Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (D-/R-). Transpl Infect Dis 2021;23:e13564. [PMID: 33449413 DOI: 10.1111/tid.13564] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Mella A, Mariano F, Dolla C, Gallo E, Manzione AM, Di Vico MC, Cavallo R, De Rosa FG, Costa C, Biancone L. Bacterial and Viral Infection and Sepsis in Kidney Transplanted Patients. Biomedicines 2022;10:701. [DOI: 10.3390/biomedicines10030701] [Reference Citation Analysis]
108 Pavlakou P, Papasotiriou M, Ntrinias T, Kourakli A, Bratsiakou A, Goumenos DS, Papachristou E. Case Report: Kidney Transplantation in a Patient With Acquired Agammaglobulinemia and SLE. Issues and Challenges. Front Med (Lausanne) 2021;8:665475. [PMID: 33777986 DOI: 10.3389/fmed.2021.665475] [Reference Citation Analysis]
109 Pham C, Kuten SA, Knight RJ, Nguyen DT, Graviss EA, Gaber AO. Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab. Transpl Infect Dis 2020;22:e13257. [PMID: 32031729 DOI: 10.1111/tid.13257] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Gugliesi F, Coscia A, Griffante G, Galitska G, Pasquero S, Albano C, Biolatti M. Where do we Stand after Decades of Studying Human Cytomegalovirus? Microorganisms 2020;8:E685. [PMID: 32397070 DOI: 10.3390/microorganisms8050685] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
111 Sung BY, Lin YH, Kong Q, Shah PD, Glick Bieler J, Palmer S, Weinhold KJ, Chang HR, Huang H, Avery RK, Schneck J, Chiu YL. Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1. J Clin Invest 2022;132:e140508. [PMID: 35040433 DOI: 10.1172/JCI140508] [Reference Citation Analysis]
112 Lin H, Chen L, Wen S, Yue Z, Mo Y, Jiang X, Huang L. Early diagnosis and successful treatment of cytomegalovirus peritonitis in children with primary nephrotic syndrome: case series and literature review. Ren Fail 2020;42:776-84. [PMID: 32757688 DOI: 10.1080/0886022X.2020.1800491] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Levi S, Davidovits M, Alfandari H, Dagan A, Borovitz Y, Bilavsky E, Landau D, Haskin O. EBV, CMV, and BK viral infections in pediatric kidney transplantation: Frequency, risk factors, treatment, and outcomes. Pediatr Transplant 2021;:e14199. [PMID: 34817112 DOI: 10.1111/petr.14199] [Reference Citation Analysis]
114 Saullo JL, Baker AW, Snyder LD, Reynolds JM, Zaffiri L, Eichenberger EM, Ferrari A, Steinbrink JM, Maziarz EK, Bacchus M, Berry H, Kakoullis SA, Wolfe CR. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis. J Heart Lung Transplant 2021:S1053-2498(21)02626-7. [PMID: 35031206 DOI: 10.1016/j.healun.2021.12.005] [Reference Citation Analysis]
115 Abidi MZ, Erlandson KM. A Comprehensive Review of Infections in Older Kidney Transplant Recipients. Curr Transpl Rep 2021;8:90-9. [DOI: 10.1007/s40472-021-00320-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Vietzen H, Rückert T, Hartenberger S, Honsig C, Jaksch P, Geleff S, Hammer Q, Romagnani C, Segura-Wang M, Puchhammer-Stöckl E. Extent of Cytomegalovirus Replication in the Human Host Depends on Variations of the HLA-E/UL40 Axis. mBio 2021;12:e02996-20. [PMID: 33727352 DOI: 10.1128/mBio.02996-20] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Eberhard S, Vietzen H, Görzer I, Jaksch P, Puchhammer-Stöckl E. Analysis and Fine Specificity of the HCMV-Specific Cell-Free and Cell-Associated Antibody-Dependent Cellular Phagocytosis (ADCP) Responses in Lung Transplant Recipients. Int J Mol Sci 2021;22:8206. [PMID: 34360986 DOI: 10.3390/ijms22158206] [Reference Citation Analysis]
118 Prakash K, Chandorkar A, Saharia KK. Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update. Diagnostics (Basel) 2021;11:875. [PMID: 34068377 DOI: 10.3390/diagnostics11050875] [Reference Citation Analysis]
119 Yoon CH, Choi HJ, Kim MK. Corneal xenotransplantation: Where are we standing? Prog Retin Eye Res 2021;80:100876. [PMID: 32755676 DOI: 10.1016/j.preteyeres.2020.100876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Agrawal A, Ison MG, Danziger-Isakov L. Long-Term Infectious Complications of Kidney Transplantation. Clin J Am Soc Nephrol 2021:CJN. [PMID: 33879502 DOI: 10.2215/CJN.15971020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Scherger S, Mathur S, Bajrovic V, Johnson SC, Benamu E, Ramanan P, Wolfel G, Levi ME, Abidi MZ. Cytomegalovirus myocarditis in solid organ transplant recipients: A case series and review of literature. Transpl Infect Dis 2020;22:e13282. [PMID: 32232951 DOI: 10.1111/tid.13282] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 La Hoz RM, Wallace A, Barros N, Xie D, Hynan LS, Liu T, Yek C, Schexnayder S, Grodin JL, Garg S, Drazner MH, Peltz M, Haley RW, Greenberg DE. Epidemiology and risk factors for varicella zoster virus reactivation in heart transplant recipients. Transpl Infect Dis 2021;23:e13519. [PMID: 33220133 DOI: 10.1111/tid.13519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Bruminhent J, Dajsakdipon T, Ingsathit A, Supaporn T, Prommool S, Watcharananan SP. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry. Transplant Proc 2020;52:829-35. [PMID: 32113693 DOI: 10.1016/j.transproceed.2020.01.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Sethi S, Peng A, Najjar R, Vo A, Jordan SC, Huang E. Infectious Complications in Tocilizumab-treated Kidney Transplant Recipients. Transplantation 2021;105:1818-24. [PMID: 33534530 DOI: 10.1097/TP.0000000000003512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
125 Di Nardo M, Tikkanen J, Husain S, Singer LG, Cypel M, Ferguson ND, Keshavjee S, Del Sorbo L. Postoperative Management of Lung Transplant Recipients in the Intensive Care Unit. Anesthesiology 2021. [PMID: 34910811 DOI: 10.1097/ALN.0000000000004054] [Reference Citation Analysis]
126 Franck B, Woillard JB, Théorêt Y, Bittencourt H, Demers E, Briand A, Marquet P, Lapeyraque AL, Ovetchkine P, Autmizguine J. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients. Br J Clin Pharmacol 2021;87:3105-14. [PMID: 33373493 DOI: 10.1111/bcp.14719] [Reference Citation Analysis]
127 Hall VG, Humar A, Kumar D. Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation. J Clin Microbiol 2022;:e0171621. [PMID: 35543099 DOI: 10.1128/jcm.01716-21] [Reference Citation Analysis]
128 Tan HZ, Choo JCJ, Tan BH, Mok IYJ, Lim CC. Cytomegalovirus preventive strategies in lupus nephritis and renal vasculitis treated with immunosuppressants. Lupus 2020;29:351-2. [PMID: 31986963 DOI: 10.1177/0961203320902532] [Reference Citation Analysis]
129 Jorgenson MR, Descourouez JL, Wong C, Strayer JR, Parajuli S, Rice JP, Redfield RR, Smith JA, Mandelbrot DA, Saddler CM. Cytomegalovirus antiviral stewardship in the COVID-19 Era: Increasing complexity of prophylaxis and treatment and potential mitigation strategies. Transpl Infect Dis 2021;:e13586. [PMID: 33595158 DOI: 10.1111/tid.13586] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Rodríguez-Goncer I, Fernández-Ruiz M, Aguado JM. A critical review of the relationship between post-transplant atherosclerotic events and cytomegalovirus exposure in kidney transplant recipients. Expert Rev Anti Infect Ther 2020;18:113-25. [PMID: 31852276 DOI: 10.1080/14787210.2020.1707079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Fu L, Santhanakrishnan K, Al-Aloul M, Jones NP, Steeples LR. Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches. Ocul Immunol Inflamm 2020;28:1152-8. [PMID: 31621449 DOI: 10.1080/09273948.2019.1645188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Cervera-Hernandez ME, Ikemura K, McCort ME. Cytomegalovirus skin disease in a kidney transplant patient. BMJ Case Rep 2021;14:e236903. [PMID: 34226250 DOI: 10.1136/bcr-2020-236903] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Non LR, Ince D. Infectious Gastroenteritis in Transplant Patients. Gastroenterol Clin North Am 2021;50:415-30. [PMID: 34024449 DOI: 10.1016/j.gtc.2021.02.013] [Reference Citation Analysis]
134 Roberts SC, Ison MG. Donor-Derived Disease Transmission in Lung Transplantation. Curr Pulmonol Rep 2020;9:1-9. [DOI: 10.1007/s13665-020-00245-z] [Reference Citation Analysis]
135 Das BB, Prusty BK, Niu J, Sue PK. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis. Pediatr Transplant 2020;24:e13750. [PMID: 32573886 DOI: 10.1111/petr.13750] [Reference Citation Analysis]
136 Bruminhent J, Bushyakanist A, Kantachuvesiri S, Kiertiburanakul S. A Nationwide Survey of Cytomegalovirus Prevention Strategies in Kidney Transplant Recipients in a Resource-Limited Setting. Open Forum Infect Dis 2019;6:ofz322. [PMID: 31660402 DOI: 10.1093/ofid/ofz322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
137 Minz RW, Kumar M, Kanwar DB, Sharma A, Singh P, Singh J, Singh S, Anand S, Sakhuja V, Minz M. Cytomegalovirus Infection in Postrenal Transplant Recipients: 18 Years’ Experience From a Tertiary Referral Center. Transplantation Proceedings 2020;52:3173-8. [DOI: 10.1016/j.transproceed.2020.02.162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
138 Shi Y, Lerner AH, Rogers R, Vieira K, Merhi B, Mecadon K, Osband AJ, Bayliss G, Gohh R, Morrissey P, Farmakiotis D. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients. Prog Transplant 2021;31:368-76. [PMID: 34839729 DOI: 10.1177/15269248211046037] [Reference Citation Analysis]
139 Singh N, Winston DJ, Razonable RR, Lyon GM, Huang ML, Jerome KR, Silveira FP, Wagener MM, Limaye AP. Association of HHV-6 With Outcomes in CMV-seronegative Liver Transplant Recipients With CMV-seropositive Donors Receiving Preemptive Antiviral Therapy. Transplantation 2021;105:2427-34. [PMID: 33587431 DOI: 10.1097/TP.0000000000003604] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Saeed H, Thoendel M, Razonable RR. Individualized management of cytomegalovirus in solid organ transplant recipients. Expert Review of Precision Medicine and Drug Development 2021;6:333-44. [DOI: 10.1080/23808993.2021.1964951] [Reference Citation Analysis]
141 Yu U, Wang X, Zhang X, Wang C, Yang C, Zhou X, Li Y, Huang X, Wen J, Wen F, Liu S. Cytomegalovirus Infection and the Implications of Drug-Resistant Mutations in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Retrospective Study from a Tertiary Hospital in China. Infect Dis Ther 2021;10:1309-22. [PMID: 33966176 DOI: 10.1007/s40121-021-00452-4] [Reference Citation Analysis]
142 Sise ME, Goldberg DS, Schaubel DE, Fontana RJ, Kort JJ, Alloway RR, Durand CM, Blumberg EA, Woodle ES, Sherman KE, Brown RS, Friedewald JJ, Desai NM, Sultan ST, Levitsky J, Lee MD, Strohbehn IA, Landis JR, Fernando M, Gustafson JL, Chung RT, Reese PP. One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. Kidney International Reports 2022;7:241-50. [DOI: 10.1016/j.ekir.2021.11.022] [Reference Citation Analysis]
143 Harris CE, Issa NC. Risk constellations, viral infections, and prophylaxis in uterine transplantation. Curr Opin Organ Transplant 2021;26:646-53. [PMID: 34620783 DOI: 10.1097/MOT.0000000000000927] [Reference Citation Analysis]
144 Shiraki K, Takemoto M, Daikoku T. Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment. Expert Rev Anti Infect Ther 2021;:1-11. [PMID: 33853490 DOI: 10.1080/14787210.2021.1917992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Yeh P, Wu R, Chiu C, Lai M, Chen C, Pan Y, Su M, Kuo C, Lin W, Le P. Cytomegalovirus Diseases of the Gastrointestinal Tract. Viruses 2022;14:352. [DOI: 10.3390/v14020352] [Reference Citation Analysis]
146 Pongsakornkullachart K, Chayakulkeeree M, Vongwiwatana A, Kantakamalakul W, Skulratanasak P, Phoompoung P. QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country. Front Cell Infect Microbiol 2022;12:893232. [DOI: 10.3389/fcimb.2022.893232] [Reference Citation Analysis]
147 Cachera L, Adenis A, Dueymes JM, Rochemont D, Guarmit B, Roura R, Meddeb M, Nacher M, Djossou F, Epelboin L; ITRAG Working Group. What Is the Part of Tropical Diseases Among Infectious Complications in Renal Transplant Recipients in the Amazon? A 12-Year Multicenter Retrospective Analysis in French Guiana. Transplant Proc 2021;53:2242-51. [PMID: 34474909 DOI: 10.1016/j.transproceed.2021.07.038] [Reference Citation Analysis]
148 Bruminhent J, Razonable R. Advances in drug therapies for cytomegalovirus in transplantation: a focus on maribavir and letermovir. Expert Opinion on Orphan Drugs 2020;8:393-401. [DOI: 10.1080/21678707.2020.1835639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
149 Shiraki K, Yasumoto S, Toyama N, Fukuda H. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster. Viruses 2021;13:1547. [PMID: 34452412 DOI: 10.3390/v13081547] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Raghu VK, Vetterly CG, Horslen SP. Immunosuppression Regimens for Intestinal Transplantation in Children. Pediatr Drugs. [DOI: 10.1007/s40272-022-00512-3] [Reference Citation Analysis]
151 Rogers R, Saharia K, Chandorkar A, Weiss ZF, Vieira K, Koo S, Farmakiotis D. Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events. BMC Infect Dis 2020;20:58. [PMID: 31952516 DOI: 10.1186/s12879-020-4787-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
152 Arias-Murillo YR, Benavides-V CA, Salinas-N MA, Osorio-Arango K, Plazas-Sierra C, Cortés JA. SARS-CoV2/COVID-19 Infection in Transplant Recipients and in Patients on the Organ Transplant Waiting List in Colombia. Transplant Proc 2021;53:1237-44. [PMID: 33558085 DOI: 10.1016/j.transproceed.2020.12.003] [Reference Citation Analysis]